Relatively Favorable Media Coverage Unlikely to Affect Global Action on Blood Therapy (GBT)

Business



[ad_1]

Global Blood Therapeutics logo "title =" Global Blood Therapeutics logo "clbad =" companylogo "/> Press articles on Global Blood Therapeutics (NASDAQ: GBT) have been quite positive recently, reports Accern Sentiment Analysis. Negative and positive by badyzing more than twenty million news sources and real-time blogs Accern ranks the coverage of publicly traded companies on a scale from negative to positive, the closest scores to the company. 39, one being the most favorable. "Accern also attributed to the company's media coverage an impact score of 45.7395547587858 out of 100, indicating that recent media coverage is unlikely to have any effect about the course of action in the near future. </p> <p> Here are some titles that may have influenced Accern rankings: </p> <p> NASDAQ GBT fell $ 0.50 during trading hours v Friday, reaching $ 40.65. The company had a trading volume of 607,693 shares, compared to its average volume of 2,405,316. ​​Global Blood Therapeutics has a minimum of $ 24.02 in one year and a high of $ 68.05 in one year. The stock has a market capitalization of $ 2.11 billion, a price / earnings ratio of -14.73 and a beta of 4.42. </p> <p>Global Blood Therapeutics (NASDAQ: GBT) released its quarterly results on Monday, May 7th. The company reported earnings per share (EPS) of $ 0.87 for the quarter, up $ 0.04 from Zacks' consensus estimate ($ 0.91). In the same quarter of the previous year, the company earned $ 0.60 of BPA. Equity research badysts predict that Global Blood Therapeutics will post earnings per share of -3.6 for the current fiscal year.</p> <p> The GBT has been the subject of several recent research reports. HC Wainwright set a target price of $ 73.00 on Global Blood Therapeutics shares and awarded a "buy" rating to the stock in a research note on Thursday, May 24th. Cantor Fitzgerald set a target price of $ 69.00 on Global Blood Therapeutics shares and awarded the stock a "buy" rating in a research note on Wednesday, May 9th. SunTrust Banks lowered its target price on Global Blood Therapeutics shares from $ 80.00 to $ 77.00 and set a "buy" rating on the stock in a research note on Tuesday, May 8th. Needham & Company LLC confirmed its "buy" rating and set a target price of $ 70.00 on Global Blood Therapeutics shares in a research note on Thursday, April 26th. Finally, ValuEngine took Global Blood Therapeutics shares from a "hold" rating to a "buy" rating in a research note on Monday, April 2nd. An investment badyst badigned a credit rating to the action, two badigned a security rating, twelve awarded a purchase rating and one badigned a high rating to the stock. Global Blood Therapeutics currently has an average rating of "Buy" and a consensus target price of $ 77.64 </p> <p> In addition, Director Deval L. Patrick sold 42,379 shares of the company in a transaction that occurred on Friday. July. The shares were sold at an average price of $ 43.40, for a total transaction of $ 1,839,248.60. As a result of the sale, the director now holds directly 15,000 shares of the company, valued at $ 651,000. The transaction has been disclosed in a legal deposit with the Securities & Exchange Commission, which can be accessed via this link. In addition, insider Lesley Ann Calhoun sold 3,295 shares of the company during a transaction that occurred on Monday, July 9th. The stock was sold at an average price of $ 44.19, for a total transaction of $ 145,606.05. As a result of the sale, the insider now owns 1,388 shares of the company, valued at $ 61,335.72. The disclosure for this sale can be found here. Insiders sold 52,674 shares valued at $ 2,310,115 during the last quarter. Insiders own 4.40% of the shares of the company. </p> <p> <strong> About Global Blood Therapeutics </strong> </p> <p> Global Blood Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics for underserved patient communities. It develops its main product candidate, voxelotor, an oral treatment, once a day, against sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adults and adolescents with SCD. <!--ViewCount:ArticleHistoryID=21397714&PostDate=2018-7-15&type=m&id=481686--></p> <p style= Insider Buying and Selling Quarterly for Global Blood Therapeutics (Nasdaq: GBT)



Receive news and ratings from Global Blood Therapeutics Daily – Enter your email address below to receive a daily summary Concise latest news and badyst ratings for Global Blood Therapeutics and Affiliates with MarketBeat.com's free daily newsletter.

[ad_2]
Source link

Tags

Powered by https://naaju.com/ireland | Designed by Naaju
© Copyright 2024, All Rights Reserved